|Bid||70.75 x 100000|
|Ask||70.91 x 100000|
|Day's Range||70.43 - 70.68|
|52 Week Range||62.10 - 80.00|
|PE Ratio (TTM)||22.16|
|Forward Dividend & Yield||0.69 (0.86%)|
|1y Target Est||83.18|
New York-based Senvest Management is shorting three drug stocks, Insys Therapeutics Inc , Akorn Inc and Fresenius SE, its chief executive Richard Mashaal said on Tuesday, Speaking at the Sohn Conference ...
Fresenius Medical's (FMS) latest development is expected to fortify the company's foothold in the Home dialysis market, particularly in the renal care space.
Fresenius’s minority-owned kidney dialysis business agreed to acquire NxStage Medical Inc. for about $2 billion.
E*TRADE Financial Corporation, Big Five Sporting Goods, Micron Technology, Electrolux AB and Fresenius SE & Co. highlighted as Zacks Bull and Bear of the Day
The Bad Homburg, Germany-based company said it had profit of 48 cents per share. The dialysis services provider posted revenue of $4.92 billion in the period. Fresenius shares have increased 12 percent ...
Nestle SA Chief Executive Officer Mark Schneider previously transformed a sleepy German hospital operator into a stock-market darling via more than 30 acquisitions. Now he wants to return to dealmaking ...
For all the problems with US healthcare, there’s one service that’s been fully funded by the government since 1972. During his troubled tenure as president, Richard Nixon signed a bill into law that provided access to dialysis—a process which externally filters the blood when kidneys fail to do so—to anyone who needs it. As of…
European shares slipped slightly from the 20-month highs they hit in the previous session, as investors locked in some profits following some underwhelming company results. Shares in several Apple suppliers fell after the smartphone giant reported a surprise dip in sales of its flagship iPhone. Dialog Semiconductor shares slid 2.9 percent at the open.
Fresenius announced a deal to buy U.S. generic drugmaker Akorn Inc for $4.75 billion, or $34 per share.
Fresenius announced a deal to buy U.S. generic drugmaker Akorn Inc for $4.75 billion and the biosimilars unit of German peer Merck KGaA.
German healthcare group Fresenius SE & Co KGaA (FREG.DE) has stepped up its dealmaking, agreeing to buy U.S. generic drugmaker Akorn Inc (AKRX.O) for $4.75 billion (4.37 billion euros) and the biosimilars arm of Germany's Merck KGaA. Takeovers were part of Fresenius's growth strategy under previous boss Ulf Mark Schneider, now leading Nestle (NESN.S). The latest deals are in keeping with Fresenius's focus on drugs that have lost patent protection, but also mark a foray into new dosage forms, therapeutic areas and biotech drugs for its Kabi unit, a maker of generic infusion drugs as well as tube feeding and blood transfusion equipment.
In just 10 months at the head of Germany’s Fresenius SE, Chief Executive Officer Stephan Sturm has now inked the health-care provider’s two biggest-ever deals.
Acquiring Akorn would add around $1 billion in annual sales to Fresenius' drugmaking division, giving it a significantly larger presence in eyecare and other areas widely perceived as somewhat insulated from generic drug pricing pressure. The deal values Akorn in the region of $33 to $35 per share, said the sources. Akorn shares were hovering around $32 on Monday afternoon in New York, up by more than a third since April 7, when it confirmed it was in talks with Fresenius about a potential deal.
A drugmaker asked Arkansas officials not to purchase its products for executions months before the state accepted a third-party "donation" of potassium chloride as one of three drugs to use in ...
LITTLE ROCK, Ark. (AP) — Two pharmaceutical companies asked a federal judge Thursday to prevent Arkansas from using their drugs to execute seven inmates by the end of the month, saying they object to their products being used for capital punishment.
Akorn stock gapped up 10% Monday, after confirmation late Friday that it's in talks to be acquired by Fresenius Kabi.